- Home
- CHRS vs NRO Comparison
CHRS vs NRO Comparison
Compare CHRS & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- NRO
- Stock Information
- Founded
- CHRS 2010
- NRO 2003
- Country
- CHRS United States
- NRO United States
- Employees
- CHRS 235
- NRO N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- NRO Finance/Investors Services
- Sector
- CHRS Health Care
- NRO Finance
- Exchange
- CHRS Nasdaq
- NRO Nasdaq
- Market Cap
- CHRS 134.4M
- NRO 170.5M
- IPO Year
- CHRS 2014
- NRO N/A
- Fundamental
- Price
- CHRS $1.16
- NRO $3.31
- Analyst Decision
- CHRS Strong Buy
- NRO
- Analyst Count
- CHRS 4
- NRO 0
- Target Price
- CHRS $5.38
- NRO N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- NRO 239.4K
- Earning Date
- CHRS 03-12-2025
- NRO 01-01-0001
- Dividend Yield
- CHRS N/A
- NRO 11.41%
- EPS Growth
- CHRS N/A
- NRO N/A
- EPS
- CHRS N/A
- NRO N/A
- Revenue
- CHRS $304,340,000.00
- NRO N/A
- Revenue This Year
- CHRS $2.47
- NRO N/A
- Revenue Next Year
- CHRS N/A
- NRO N/A
- P/E Ratio
- CHRS N/A
- NRO N/A
- Revenue Growth
- CHRS 44.19
- NRO N/A
- 52 Week Low
- CHRS $0.66
- NRO $2.51
- 52 Week High
- CHRS $2.87
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- NRO 38.13
- Support Level
- CHRS $1.03
- NRO $3.33
- Resistance Level
- CHRS $1.39
- NRO $3.45
- Average True Range (ATR)
- CHRS 0.14
- NRO 0.07
- MACD
- CHRS -0.03
- NRO -0.01
- Stochastic Oscillator
- CHRS 14.04
- NRO 5.56
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").